Wanbang Pharmaceutical (301520.SZ): The information related to the progress of the innovative drug paclitaxel controlled-release tablets and the signing of new drug cooperation agreements such as amyotrophic lateral sclerosis are all false information.

Zhitong Finance and Economics App News, Wanbang Medicine (301520.SZ) issued a public announcement on abnormal stock trading fluctuations and risk warnings, stating that the company recently noticed that there were media and stock community reports on platforms like Stock Bar stating that the information related to the company's advancement of the core pipeline innovative drug Taxus Alkaloid Methoxy Sustained-release Tablets and signing new drug cooperation agreements for diseases such as amyotrophic lateral sclerosis (ALS) are all false information; the company has not disclosed its performance for the first half of 2026 to the public, nor has it released any performance forecasts.